Available Now: NAVLIN by EVERSANA's “Last Week in Review,” recapping the latest regulatory changes, pricing & reimbursement updates, and drug approvals across the world.
This week:
Policy: Italy's AIFA, under new leadership, approves regulations for its Scientific-Economic Commission (CSE), ensuring robust decision-making in drug evaluations.
Pricing & Reimbursement: New Zealand’s Pharmac clears bundle deal for funding ovarian cancer drug Zejula, triple inhaler Trelegy Ellipta, and HIV drug Dovato, expanding access to critical treatments.
HTA: France’s HAS grants pre-MA early access for MSD’s Sotatercept to treat pulmonary arterial hypertension in adults, offering hope for patients with this condition.
Drug Approval: Janssen's Rybrevant approved in Brazil for advanced or metastatic NSCLC with specific mutations, providing a new treatment option for patients.
C&G Therapy: A U.S. bill seeks to restrict foreign companies like WuXi from doing business with the U.S., impacting drug ingredients for various treatments, raising concerns about supply chain disruptions.
Conferences: Reuters Pharma Europe emphasizes collaboration across sectors and governments to ensure patient access to medicines, highlighting the importance of collective efforts in healthcare.
Supply Issues: U.S. prescription drug shortages hit a new high in Q1 2024, with 323 ongoing shortages, posing challenges to healthcare delivery and patient care.
And more...
READ MORE: https://ow.ly/sMXa50RlyJY